RELN and melanoma: We observed that both mutations exhibited preferable ICI treatment prognoses in melanoma and NSCLC patients after mutually adjusting (all HR < 1, all p < 0.05; Figures S8 and S9), which suggests that RELN and FAT1 mutations are two independent biomarkers for predicting ICI response.